1. expected survival or time to withdrawal of life-sustaining treatments expected to be \<7 days. 2. ecmo; 3. suspected septic shock; 4. the patient has a history of: * organ or hematologic transplant; * hiv; * active hepatitis b or hepatitis c infection; 5. current treatment with: * chemotherapy; * immunosuppressive medications or immunotherapy (see section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; * hemodialysis or peritoneal dialysis; 6. the patient is known to be pregnant or is nursing; 7. currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; 8. allergy to eggs or any of the excipients in study drug.

1. expected survival or time to withdrawal of life-sustaining treatments expected to be \<7 days. 2. ecmo; 3. suspected septic shock; 4. the patient has a history of: * organ or hematologic transplant; * hiv; * active hepatitis b or hepatitis c infection; 5. current treatment with: * chemotherapy; * immunosuppressive medications or immunotherapy (see section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; * hemodialysis or peritoneal dialysis; 6. the patient is known to be pregnant or is nursing; 7. currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; 8. allergy to eggs or any of the excipients in study drug.

expected survival or time to withdrawal of life-sustaining treatments expected to be <7 days. ecmo; suspected septic shock; the patient has a history of: organ or hematologic transplant; hiv; active hepatitis b or hepatitis c infection; current treatment with: chemotherapy; immunosuppressive medications or immunotherapy (see section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; hemodialysis or peritoneal dialysis; the patient is known to be pregnant or is nursing; currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; allergy to eggs or any of the excipients in study drug.

expected survival or time to withdrawal of life-sustaining treatments expected to be <7 days. ecmo; suspected septic shock; the patient has a history of: organ or hematologic transplant; hiv; active hepatitis b or hepatitis c infection; current treatment with: chemotherapy; immunosuppressive medications or immunotherapy (see section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; hemodialysis or peritoneal dialysis; the patient is known to be pregnant or is nursing; currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; allergy to eggs or any of the excipients in study drug.

1. expected survival or time to withdrawal of life-sustaining treatments expected to be <7 days. 2. ecmo; 3. suspected septic shock; 4. the patient has a history of: - organ or hematologic transplant; - hiv; - active hepatitis b or hepatitis c infection; 5. current treatment with: - chemotherapy; - immunosuppressive medications or immunotherapy (see section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; - hemodialysis or peritoneal dialysis; 6. the patient is known to be pregnant or is nursing; 7. currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; 8. allergy to eggs or any of the excipients in study drug.

1. expected survival or time to withdrawal of life-sustaining treatments expected to be <7 days. 2. ecmo; 3. suspected septic shock; 4. the patient has a history of: - organ or hematologic transplant; - hiv; - active hepatitis b or hepatitis c infection; 5. current treatment with: - chemotherapy; - immunosuppressive medications or immunotherapy (see section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; - hemodialysis or peritoneal dialysis; 6. the patient is known to be pregnant or is nursing; 7. currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; 8. allergy to eggs or any of the excipients in study drug.